UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 21, 2015
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 001-14041 | 04-2882273 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
| 400 Wood Road, Braintree Massachusetts | 02184 | |
| (Address of principal executive offices) | Zip code | |
Registrant's telephone number, including area code 781-848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR
Amendment to By-laws
On January 21, 2015, the Board of Directors of Haemonetics Corporation amended Article II of its By-Laws to require shareholders proposing business at the Annual Meeting of Shareholders to disclose certain details regarding their proposal and their economic interests, including derivative equity ownership.
The full text of the By-Laws of Haemonetics Corporation, as amended through January 21, 2015, is attached as Exhibit 99.1, and is incorporated herein by reference.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
99.1 By-Laws of Haemonetics Corporation, as amended through January 21, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||
| (Registrant) | ||
Date: January 27, 2015 | By: | /s/ Christopher Lindop |
| Christopher Lindop, Chief Financial Officer and | ||
| Executive Vice President Business Development | ||